The latest probe points to challenges for India’s biggest drugmaker after whistle-blower complaints on corporate governance lapses triggered a stock slide last year.
In 2015, billionaire Dilip Shanghvi bought 23% stake for Rs 18 billion, but Suzlon still hasn’t exited India’s debt-restructuring program, missing deadlines since 2017.
Finance ministry says the proposed revamp will focus on structural reforms, rate rationalisation & ease of living, & will be deliberated upon in the coming weeks.
The project is meant to be a ‘protective shield that will keep expanding’, the PM said. It is on the lines of the ‘Golden Dome’ announced by Trump, it is learnt.
Standing up to America is usually not a personal risk for a leader in India. Any suggestions of foreign pressure unites India behind who they see as leading them in that fight.
Big Pharma, such as, Johnson and Johnson, Abbott, Purdue that were responsible for causing opioid crisis in USA are shifting their shops to India to peddle their poison here. They are facing immense pressure in US with a slew of court filings and billions in restitution.
Source: https://www.theguardian.com/world/2019/aug/27/india-opioids-crisis-us-pain-narcotics
Big Pharma, such as, Johnson and Johnson, Abbott, Purdue that were responsible for causing opioid crisis in USA are shifting their shops to India to peddle their poison here. They are facing immense pressure in US with a slew of court filings and billions in restitution.
Source: https://www.theguardian.com/world/2019/aug/27/india-opioids-crisis-us-pain-narcotics